DB
CODX

Danske Bank’s Co-Diagnostics CODX Stock Holding History

Danske Bank’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$13 – 1170
2026
Q1 		$13 Buy
+7
New +$24 ﹤0.01% 1081

Other funds holding CODX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAG
Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $3.08B AUM 27.39% 1-Year Est. Return

Danske Bank's CODX Position: Q2 2026 in Review

Danske Bank sold out of Co-Diagnostics (CODX) in Q2 2026, closing a stake of 7 shares — an estimated $13 sold.

Danske Bank first reported a position in CODX in Q1 2026 and held it in 1 quarter. The position peaked at $13 in Q1 2026. 16 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

  • Danske Bank reported no remaining Co-Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Danske Bank sold 7 Co-Diagnostics shares in Q2 2026, an estimated $13.
  • Danske Bank first reported a position in Co-Diagnostics in Q1 2026 and held it in 1 quarter.
  • Danske Bank's Co-Diagnostics position peaked at $13 in Q1 2026.
  • 16 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.